10.09.19
NSF International has acquired a majority interest in Amarex Clinical Research, LLC, a clinical stage contract research organization (CRO) headquartered in Germantown, MD. As part of NSF’s global health science consulting business, the CRO will be known as Amarex Clinical Research, LLC, an NSF International company.
Amarex will gain access to NSF’s network and international scale and will continue to operate from its U.S. office. The company also operates an office in Taiwan and has a developing presence in Europe. As part of NSF International, Amarex will support companies with regulatory affairs, project/trial management, clinical operations, biostatistics, data management, pharmacovigilance, data monitoring committees, medical writing and consulting.
“Together with Amarex, we are creating a single source for integrated, expert health science consulting services across the entire product lifecycle,” said NSF International president and chief executive officer Kevan Lawlor. “Amarex brings clinical trial expertise to NSF International’s large base of training, quality and consulting clients, and Amarex’s CRO clients may now benefit from NSF International’s global reach and expertise in European Union Qualified Person and Medical Device Regulation training, chemistry manufacturing and controls support, and supplement testing inspection and certification.”
“Amarex is excited to join the NSF International family. Amarex will be able to leverage NSF International’s global infrastructure to expand our contract research capabilities and better serve clients with the design and execution of clinical trials and navigating the FDA, TFDA and EMA regulatory approval process,” said Amarex founder Dr. Kazem Kazempour, who will continue as president and chief executive officer of Amarex, an NSF International company.
Amarex will gain access to NSF’s network and international scale and will continue to operate from its U.S. office. The company also operates an office in Taiwan and has a developing presence in Europe. As part of NSF International, Amarex will support companies with regulatory affairs, project/trial management, clinical operations, biostatistics, data management, pharmacovigilance, data monitoring committees, medical writing and consulting.
“Together with Amarex, we are creating a single source for integrated, expert health science consulting services across the entire product lifecycle,” said NSF International president and chief executive officer Kevan Lawlor. “Amarex brings clinical trial expertise to NSF International’s large base of training, quality and consulting clients, and Amarex’s CRO clients may now benefit from NSF International’s global reach and expertise in European Union Qualified Person and Medical Device Regulation training, chemistry manufacturing and controls support, and supplement testing inspection and certification.”
“Amarex is excited to join the NSF International family. Amarex will be able to leverage NSF International’s global infrastructure to expand our contract research capabilities and better serve clients with the design and execution of clinical trials and navigating the FDA, TFDA and EMA regulatory approval process,” said Amarex founder Dr. Kazem Kazempour, who will continue as president and chief executive officer of Amarex, an NSF International company.
